M&T Bank Corp Trims Position in Boston Scientific Corporation $BSX

M&T Bank Corp lessened its stake in Boston Scientific Corporation (NYSE:BSX) by 74.5% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 20,641 shares of the medical equipment provider’s stock after selling 60,258 shares during the quarter. M&T Bank Corp’s holdings in Boston Scientific were worth $1,968,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in Boston Scientific by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider’s stock worth $13,497,294,000 after buying an additional 1,115,337 shares during the period. Invesco Ltd. increased its stake in Boston Scientific by 0.7% in the 3rd quarter. Invesco Ltd. now owns 16,963,344 shares of the medical equipment provider’s stock worth $1,656,131,000 after buying an additional 111,826 shares during the period. Northern Trust Corp increased its stake in Boston Scientific by 0.9% in the 3rd quarter. Northern Trust Corp now owns 14,402,636 shares of the medical equipment provider’s stock worth $1,406,129,000 after buying an additional 128,188 shares during the period. Amundi increased its stake in Boston Scientific by 17.5% in the 3rd quarter. Amundi now owns 11,981,584 shares of the medical equipment provider’s stock worth $1,158,619,000 after buying an additional 1,781,830 shares during the period. Finally, Legal & General Group Plc increased its stake in Boston Scientific by 4.6% in the 3rd quarter. Legal & General Group Plc now owns 10,457,175 shares of the medical equipment provider’s stock worth $1,020,934,000 after buying an additional 463,889 shares during the period. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Heart Rhythm 2026 clinical data: Boston Scientific reported favorable trial results for its FARAPULSE PFA platform and WATCHMAN FLX LAAC (superiority vs antiarrhythmics for persistent AF, plus positive safety/effectiveness outcomes) — data that supports growth in electrophysiology and stroke‑care franchises. Boston Scientific Trial Wins Highlight Growth Potential In Electrophysiology And Stroke Care
• Neutral Sentiment: Valuation/opportunistic commentary: Some analysts and outlets argue BSX’s share price and valuation now look attractive after the decline, suggesting potential for a rebound if execution and integration issues are resolved. This is an investor‑opinion piece rather than new operational data. Massively Disappointing Boston Scientific (BSX) Stock Could Be Due for a Comeback
• Negative Sentiment: Broad surge of securities‑fraud notices and lead‑plaintiff solicitations: Multiple law firms have filed/announced class actions and are soliciting BSX investors who bought shares between July 23, 2025 and Feb 3, 2026; firms are urging claims and reminding investors of the May 4 lead‑plaintiff deadline — this increases legal risk, potential litigation costs and near‑term uncertainty. BSX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Boston Scientific (BSX) Investors of Securities Class Action Deadline on May 4, 2026
• Negative Sentiment: Analyst downgrades, 52‑week low and deal concerns: Coverage notes that analysts have trimmed targets after a guidance reduction and issues tied to the Penumbra transaction, and BSX hit a 52‑week low — these factors are pressuring the stock and investor sentiment. Boston Scientific (BSX) Stock Plunges to 52-Week Low: Analyst Downgrades Pile Up
• Negative Sentiment: Multiple law‑firm notices and related allegations: Additional firms (Rosen, Pomerantz, Bronstein, Portnoy, Bernstein, Gross, etc.) have issued alerts and filings alleging misstated outlooks or concealed weak U.S. electrophysiology sales — amplifies reputational and legal overhang. INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Boston Scientific Corporation of Class Action Lawsuit and Upcoming Deadlines – BSX

Analyst Ratings Changes

Several research analysts recently commented on BSX shares. UBS Group reduced their price target on shares of Boston Scientific from $120.00 to $105.00 and set a “buy” rating on the stock in a research note on Tuesday, March 17th. Sanford C. Bernstein reaffirmed an “outperform” rating and issued a $112.00 price target on shares of Boston Scientific in a research note on Friday, February 6th. JPMorgan Chase & Co. reduced their price target on shares of Boston Scientific from $135.00 to $100.00 and set an “overweight” rating on the stock in a research note on Thursday, February 5th. Barclays cut their target price on shares of Boston Scientific from $124.00 to $96.00 and set an “overweight” rating on the stock in a research report on Thursday, April 23rd. Finally, Robert W. Baird cut their target price on shares of Boston Scientific from $86.00 to $78.00 and set an “outperform” rating on the stock in a research report on Thursday, April 23rd. One analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $93.91.

Boston Scientific Stock Down 2.5%

NYSE:BSX opened at $58.46 on Wednesday. Boston Scientific Corporation has a fifty-two week low of $58.02 and a fifty-two week high of $109.50. The stock has a market capitalization of $86.88 billion, a P/E ratio of 24.46, a P/E/G ratio of 1.10 and a beta of 0.78. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. The company’s 50-day simple moving average is $67.80 and its 200-day simple moving average is $85.11.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. Boston Scientific had a net margin of 17.29% and a return on equity of 19.68%. The business had revenue of $5.20 billion for the quarter, compared to analysts’ expectations of $5.19 billion. During the same period last year, the business earned $0.75 EPS. The company’s revenue was up 11.6% compared to the same quarter last year. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, equities analysts anticipate that Boston Scientific Corporation will post 3.38 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer directly owned 1,411,735 shares in the company, valued at $131,983,105.15. This trade represents a 10.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.34% of the stock is owned by company insiders.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.